Autres langues Pluri Inc.

Actions

PLUR

US72942G2030

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
1,480 ^USD	-10,84%		-15,91%	-50,50%

28/07	Cellav Health and Aesthetics Ltd finalise l'enregistrement réglementaire de Regenativo+ au Royaume-Uni	CI
22/06	Pluri Inc. annonce des changements au sein de son conseil d’administration et de ses comités	CI

Autres langues

17/08	Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
17/08	Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform
28/07	Cellav Health and Aesthetics Ltd Completes Regulatory Registration of Regenativo+ in the UK
28/07	Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
14/07	Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
22/06	Pluri Inc. Announces Board and Board Committee Changes
02/06	Cellav Health and Aesthetics Ltd Completes Development and U.S. Cosmetic Product Listings of Regenativo+ and Placento+
02/06	Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
01/06	Pluri Biotech Ltd., Pluristem Gmbh, and Pluri Inc. Remain in Constructive Discussions with European Investment Bank Regarding EUR 20 Million Loan
15/05	Pluri: Fiscal Q3 Earnings Snapshot
14/05	Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026
19/04	Pluri : Company deck – Q2 2026
26/03	Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
26/03	Pluri Inc. announced that it expects to receive $2.5 million in funding
18/02	Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
12/02	Pluri: Fiscal Q2 Earnings Snapshot
12/02	Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025
22/01	Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
22/01	Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
22/12	Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
22/12	Pluri, Inc. Announces Expansion of Its Manufacturing Agreement with Remedy Cell Ltd
09/12	Pluri Inc. Announces Chairman of the Board of Directors Changes
09/12	Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
08/12	Pluri Inc. announced that it expects to receive $2.5 million in funding from Chutzpah Holdings Limited
13/11	Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year